Esperion Therapeutics (ESPR) Short-term Investments (2013 - 2023)

Esperion Therapeutics' Short-term Investments history runs 11 years deep, the most recent figure standing at $17.4 million for Q1 2023.

• Quarterly Short-term Investments fell 74.42% year-over-year to $17.4 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $17.4 million (down 74.42% YoY) and the FY2022 annual result came in at $42.1 million, down 16.56% from the prior year.
• Short-term Investments was $17.4 million for Q1 2023 at Esperion Therapeutics, down from $42.1 million in the prior quarter.
• Across five years, Short-term Investments topped out at $68.1 million in Q1 2022 and bottomed at $2.2 million in Q2 2020.
• A 5-year average of $35.7 million and a median of $33.3 million in 2019 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2020 — Short-term Investments slumped 91.64% — and 2022, when it fell 16.56%.
• Esperion Therapeutics' Short-term Investments stood at $34.7 million in 2019, then plunged by 93.52% to $2.2 million in 2020, then jumped by 2144.82% to $50.4 million in 2021, then declined by 16.56% to $42.1 million in 2022, then tumbled by 58.59% to $17.4 million in 2023.
• Business Quant data shows ESPR's Short-term Investments at $17.4 million in Q1 2023, $42.1 million in Q4 2022, and $29.9 million in Q3 2022.